Pharma Focus Asia

Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome

Friday, February 11, 2022

Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.

Under the terms of the revenue sharing agreement, ER-Kim gains exclusive rights to commercialize QRX003 in fifteen countries throughout the CEE including Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czechia, Hungary, Kosovo, Moldova, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

Dr. Michael Myers, Chief Executive Officer of Quoin, commented, “This is Quoin’s fifth distribution agreement for QRX003 since we went public four months ago. The agreement with ER-Kim covers a number of important countries for rare and orphan diseases in Central and Eastern Europe. ER-Kim has been a leading commercial partner for global biotech and pharma companies in its markets for over forty years and we’re excited to work with them.”

“This agreement follows the announcements of four others that encompass Latin America, the Middle East and North Africa, Russia and the CIS countries, and Australia and New Zealand. As of now, the total number of countries covered by our partnership agreements for QRX003 is 53, underscoring Quoin's absolute commitment to ensuring that every patient, everywhere, who is suffering from this devastating disease, will have access to it,” concluded Dr. Myers.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024